Finance

Lists
Why is RPGLIFE down 3,94%?
Dive Deeper
RPGLIFE:NSE
RPG Life Sciences Ltd
2 701,00 ₹
-3,94%
(-110,70) 1D
9 қаз., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for RPGLIFE...
Open
2 811,70 ₹
High
2 862,30 ₹
Low
2 671,10 ₹
Mkt. cap
45,04 млрд
Avg. vol.
32,07 мың
Volume
32,71 мың
Dividend
0,89%
Quarterly dividend
6,00 ₹
Ex-dividend date
2026 ж. 09 шіл.
P/E ratio
37,34
52-wk high
3 127,80 ₹
52-wk low
1 733,00 ₹
EPS
72,34 ₹
Shares outstanding
16,54 млн
No. of employees
1 мың
Open
2 811,70 ₹
High
2 862,30 ₹
Low
2 671,10 ₹
Mkt. cap
45,04 млрд
Avg. vol.
32,07 мың
Volume
32,71 мың
Dividend
0,89%
Quarterly dividend
6,00 ₹
Ex-dividend date
2026 ж. 09 шіл.
P/E ratio
37,34
52-wk high
3 127,80 ₹
52-wk low
1 733,00 ₹
EPS
72,34 ₹
Shares outstanding
16,54 млн
No. of employees
1 мың
News stories
From web sources and news partners
Profile
RPG Life Sciences is an Indian pharmaceutical company. Formerly known as Searle Ltd, RPG Life Sciences is part of RPG Enterprises. It has its corporate office in RPG House in Worli, Mumbai. Its three major activities are the manufacturing and marketing of bulk drugs, also known as active pharmaceutical ingredients; pharmaceutical formulation; and fermentation and biotechnology. RPGLS is present in the domestic as well as the international market. It exports its products primarily to Europe, Latin America, Australia and South East Asian countries. Wikipedia
About RPG Life Sciences Ltd
CEO-
Employees1,37 мың
Founded1993
Headquarters-
SectorPharmaceutical industry
Last report
2026 ж. 28 шіл.
Fiscal period
Q1 2027
- / -
Revenue / Est. (INR)
1,96 млрд / -
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,82 млрд
1,80 млрд
1,77 млрд
1,96 млрд
Cost of goods sold
665,80 млн
649,00 млн
661,00 млн
681,50 млн
Cost of revenue
665,80 млн
649,00 млн
661,00 млн
681,50 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
361,60 млн
353,20 млн
570,90 млн
377,60 млн
Operating expense
812,90 млн
807,50 млн
835,00 млн
901,50 млн
Total operating expenses
1,48 млрд
1,46 млрд
1,50 млрд
1,58 млрд
Operating income
338,10 млн
343,80 млн
273,30 млн
373,90 млн
Other non operating income
45,40 млн
34,10 млн
-101,90 млн
47,00 млн
EBT including unusual items
494,50 млн
291,20 млн
402,00 млн
414,60 млн
EBT excluding unusual items
382,30 млн
375,40 млн
277,30 млн
414,60 млн
Income tax expense
126,00 млн
69,90 млн
103,00 млн
107,00 млн
Effective tax rate
25,48%
24,00%
25,62%
25,81%
Other operating expenses
399,10 млн
400,50 млн
206,70 млн
464,90 млн
Net income
368,50 млн
221,30 млн
299,00 млн
307,60 млн
Net profit margin
20,28%
12,29%
16,90%
15,72%
Earnings per share
-
-
-
-
Interest and investment income
-
-
96,70 млн
-
Interest expense
-1,20 млн
-2,50 млн
-3,90 млн
-6,30 млн
Net interest expenses
-1,20 млн
-2,50 млн
92,80 млн
-6,30 млн
Depreciation and amortization charges
52,20 млн
53,80 млн
57,40 млн
59,00 млн
EBITDA
389,90 млн
395,75 млн
325,80 млн
426,40 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары